Elite Pharmaceuticals, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company developing, manufacturing, and distributing niche generic drug products with a focus on oral, controlled-release formulations. The company's core product portfolio includes immediate-release and controlled-release solid oral dose products such as lisdexamfetamine for ADHD, generic oxycodone and acetaminophen tablets, generic methotrexate sodium, generic Requip XL, and a range of products including Phentermine HCl tablets and capsules, Loxapine Succinate capsules, Naltrexone HCl tablets, Dantrolene Sodium capsules, and various amphetamine-based formulations. These products cater to therapeutic areas including central nervous system disorders, pain management, and neuropsychiatric conditions and are marketed under the Elite Laboratories label. Elite operates primarily in the United States with strategic licensing and distribution partnerships with companies such as Prasco LLC and TAGI Pharma, expanding its market reach domestically and internationally. Founded in 1985 and headquartered in Northvale, New Jersey, Elite operates a cGMP and DEA-registered manufacturing facility. Recent major company developments include the commercial launch of lisdexamfetamine products, contributing significantly to revenue growth and operating profit increases reported in fiscal 2025. The company achieved consolidated revenues of $84.0 million, a 48% increase year-over-year, and operating profits of $19.6 million, reflecting 81% growth. It has also launched generic versions of oxycodone and acetaminophen tablets, generic methotrexate sodium, and received FDA approval for generic Requip XL, expanding its specialized controlled-release drug portfolio. Elite continues to execute strategic partnerships notably with Prasco LLC, which holds non-exclusive licenses for several amphetamine extended-release products, enabling broader market penetration without substantial capital expenditure. The company maintains a robust pipeline with pending FDA approvals expected to drive further diversification and revenue expansion. These strategic expansions underline its commitment to growth within niche generics and controlled-release pharmaceuticals. Elite Pharmaceuticals continues to focus on innovation in abuse-deterrent opioid formulations and controlled-release therapies as part of its growth strategy.
Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product
Critical Comparison: Elite Pharmaceuticals (OTCMKTS:ELTP) versus Rafael (NYSE:RFL)
Elite Pharmaceuticals (OTCMKTS:ELTP) Stock Price Crosses Below Fifty Day Moving Average – Should You Sell?
Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets
Elite Pharmaceuticals (OTCMKTS:ELTP) Shares Cross Below 200-Day Moving Average – Should You Sell?
Elite Pharmaceuticals Stock Dips Post Q3 Earnings Despite Revenue Jump
Elite Pharmaceuticals, Inc. (ELTP) Q3 2026 Earnings Call Prepared Remarks Transcript
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026
ELTP Stock Declines Despite Solid Q2 Earnings and Revenue Performance
Elite Pharmaceuticals, Inc. (ELTP) Q2 2026 Earnings Call Transcript
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025
ELTP Stock Gains Following Q1 Earnings Showing Strong Revenue Growth
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information
2 Outperform Rated Small Caps with Recent Pull-backs
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025
Elite Pharmaceuticals Stock Dips Despite Record FY25 Revenue Jump
Elite Pharmaceuticals, Inc. (ELTP) Q4 2025 Earnings Call Transcript
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information